NRG-BN010: A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma

Rupesh Kotecha; Minesh Mehta

NRG-BN010: A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma

Herbert Wertheim Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - Nov 17 2022

Cite this

@conference{d08ea283ce424419b08fa0663cc82c8f,

title = "NRG-BN010: A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma",

author = "Rupesh Kotecha and Minesh Mehta",

year = "2022",

month = nov,

day = "17",

language = "American English",

}

TY - CONF

T1 - NRG-BN010: A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma

AU - Kotecha, Rupesh

AU - Mehta, Minesh

PY - 2022/11/17

Y1 - 2022/11/17

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/4683

M3 - Presentation

ER -

NRG-BN010: A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma

Other files and links

Cite this